JP2021516666A5 - - Google Patents

Info

Publication number
JP2021516666A5
JP2021516666A5 JP2020541595A JP2020541595A JP2021516666A5 JP 2021516666 A5 JP2021516666 A5 JP 2021516666A5 JP 2020541595 A JP2020541595 A JP 2020541595A JP 2020541595 A JP2020541595 A JP 2020541595A JP 2021516666 A5 JP2021516666 A5 JP 2021516666A5
Authority
JP
Japan
Prior art keywords
lymphocytes
activated
prostate cancer
approximately
myeloinfiltrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516666A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023543 external-priority patent/WO2019183455A1/en
Publication of JP2021516666A publication Critical patent/JP2021516666A/ja
Publication of JP2021516666A5 publication Critical patent/JP2021516666A5/ja
Pending legal-status Critical Current

Links

JP2020541595A 2018-03-22 2019-03-22 前立腺がん特異的髄浸潤リンパ球およびその使用 Pending JP2021516666A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646649P 2018-03-22 2018-03-22
US62/646,649 2018-03-22
PCT/US2019/023543 WO2019183455A1 (en) 2018-03-22 2019-03-22 Prostate cancer specific marrow infiltrating lymphocytes and uses thereof

Publications (2)

Publication Number Publication Date
JP2021516666A JP2021516666A (ja) 2021-07-08
JP2021516666A5 true JP2021516666A5 (https=) 2022-03-30

Family

ID=67986362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541595A Pending JP2021516666A (ja) 2018-03-22 2019-03-22 前立腺がん特異的髄浸潤リンパ球およびその使用

Country Status (11)

Country Link
US (1) US20210000876A1 (https=)
EP (1) EP3735256A4 (https=)
JP (1) JP2021516666A (https=)
KR (1) KR20200135936A (https=)
CN (1) CN112074280A (https=)
AU (1) AU2019240420A1 (https=)
CA (1) CA3084179A1 (https=)
IL (1) IL277482A (https=)
MX (1) MX2020006131A (https=)
SG (1) SG11202005200XA (https=)
WO (1) WO2019183455A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037054A1 (en) * 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
US20210338730A1 (en) * 2018-11-05 2021-11-04 Windmil Therapeutics, Inc. Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereof
MX2021006399A (es) * 2018-11-30 2021-07-15 Windmil Therapeutics Inc Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.
CN114072158A (zh) * 2019-03-22 2022-02-18 温德弥尔治疗公司 肺癌特异性骨髓浸润淋巴细胞及其用途
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
WO2017008019A1 (en) * 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
GB201608918D0 (en) * 2016-05-20 2016-07-06 Aslan Pharmaceuticals Pte Ltd Method

Similar Documents

Publication Publication Date Title
JP2021516666A5 (https=)
US20230000919A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
Zuo et al. Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice
Antonios et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
US11684659B2 (en) Tumor cell vaccines
Trzonkowski et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127− T regulatory cells
Lee et al. Tumor-infiltrating lymphocytes in melanoma
EP3773626B1 (en) Use of histone modifiers to reprogram effector t cells
RU2015138483A (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
Zhang et al. Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers
Pan et al. Donor T-cell-derived interleukin-22 promotes thymus regeneration and alleviates chronic graft-versus-host disease in murine allogeneic hematopoietic cell transplant
LaCelle et al. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy
Wu et al. Natural killer cell therapy: the key to tackle the bottleneck of cell therapies against solid tumor?
CA3200513A1 (en) Tumor cell vaccines
JP2023509388A5 (https=)
Zhu et al. Aurovertin B sensitizes colorectal cancer cells to NK cell recognition and lysis
Hoogstad-van Evert et al. Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial
Obertopp et al. Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes
Chu et al. Coupling programmed cell death 1-positive tumor-infiltrating t cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy
Teo et al. Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol)
Sarker et al. Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects
Hasan et al. Non-engineered adoptive T cell therapy
EP4565686A1 (en) Human t-cell acute lymphoblastic leukemia cell line & applications for treating cancer
Wyatt et al. DEVELOPMENT OF A TRANSLATIONAL MANUFACTURING STRATEGY FOR A NOVEL CD4+ CD26+ MESOCAR T CELL PRODUCT FOR PANCREATIC DUCTAL ADENOCARCINOMA
Goward et al. CHARACTERIZATION OF PATIENT-DERIVED TUMOR-SPECIFIC T-CELLS WITH CHECKPOINT MODIFICATIONS FOR ADOPTIVE TRANSFER USING RNA-SEQ BASED GENE EXPRESSION